Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.

ABSTRACT:

Background & aims

Alcohol use treatment such as medication-assisted therapies (MATs) and counseling are available and effective in promoting alcohol abstinence. We sought to explore the cost-effectiveness of different alcohol use treatments among patients with compensated alcohol-related cirrhosis (AC).

Methods

We simulated a cohort of patients with compensated AC receiving care from a hepatology clinic over their lifetimes. We estimated costs (in 2017 US$) and benefits in terms of quality-adjusted life years (QALYs) gained from healthcare and societal perspectives. Transition probabilities, costs, and health utility weights were taken from the literature. Treatment effects of FDA-approved MATs (acamprosate and naltrexone) and non-FDA approved MATs (baclofen, gabapentin, and

SUBMITTER: Avancena ALV 

PROVIDER: S-EPMC8177741 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature